Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants

Carl T. D'Angio, Roy J. Heyne, T. Michael O'Shea, Robert L. Schelonka, Seetha Shankaran, Shahnaz Duara, Ronald N. Goldberg, Barbara J. Stoll, Krisa P. Van Meurs, Betty R. Vohr, Abhik Das, Lei Li, Robert L. Burton, Betty Hastings, Dale L. Phelps, Pablo J. Sanchez, Waldemar A. Carlo, David K. Stevenson, Rosemary D. Higgins

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The heptavalent pneumococcal CRM197 conjugate vaccine (PCV-7) has been incompletely studied in very-low-birth-weight (≤1500 g) infants. Objective: To assess PCV-7 immunogenicity in very-low-birth-weight, premature infants. We hypothesized that the frequency of postvaccine antibody concentrations 0.15 μg/mL would vary directly with birth weight. Methods: This was a multicenter observational study. Infants 401 to 1500 g birth weight and <32 0/7 weeks gestation, stratified by birth weight, were enrolled from 9 National Institute of Child Health and Human Development Neonatal Research Network centers. Infants received PCV-7 at 2, 4, and 6 months after birth and had blood drawn 4 to 6 weeks following the third dose. Antibodies against the 7 vaccine serotypes were measured by enzyme-linked immunosorbent assay. Results: Of 369 enrolled infants, 244 completed their primary vaccine series by 8 months and had serum obtained. Subjects were 27.8 ± 2.2 (mean ± standard deviation) weeks gestation and 1008 ± 282 g birth weight. Twenty-six percent had bronchopulmonary dysplasia and 16% had received postnatal glucocorticoids. Infants 1001 to 1500 g birth weight were more likely than those 401 to 1000 g to achieve antibody concentrations 0.15 μg/mL against the least 2 immunogenic serotypes (6B: 96% vs. 85%, P = 0.003 and 23F: 97% vs. 88%, P = 0.009). In multiple logistic regression analysis, lower birth weight, postnatal glucocorticoid use, lower weight at blood draw, and Caucasian race were each independently associated with antibody concentrations <0.35 μg/mL against serotypes 6B and/or 23F. Conclusions: When compared with larger premature infants, infants weighing ≤1000 g at birth have similar antibody responses to most, but not all, PCV-7 vaccine serotypes.

Original languageEnglish
Pages (from-to)600-606
Number of pages7
JournalPediatric Infectious Disease Journal
Volume29
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Very Low Birth Weight Infant
Birth Weight
Premature Infants
Vaccines
Antibodies
Glucocorticoids
National Institute of Child Health and Human Development (U.S.)
Parturition
Pregnancy
Bronchopulmonary Dysplasia
Multicenter Studies
Antibody Formation
Observational Studies
Heptavalent Pneumococcal Conjugate Vaccine
Vaccine Immunogenicity
Logistic Models
Enzyme-Linked Immunosorbent Assay
Regression Analysis
Weights and Measures
Serogroup

Keywords

  • immunization
  • pneumococcal vaccines
  • premature infant
  • vaccines
  • very low birth weight infant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. / D'Angio, Carl T.; Heyne, Roy J.; O'Shea, T. Michael; Schelonka, Robert L.; Shankaran, Seetha; Duara, Shahnaz; Goldberg, Ronald N.; Stoll, Barbara J.; Van Meurs, Krisa P.; Vohr, Betty R.; Das, Abhik; Li, Lei; Burton, Robert L.; Hastings, Betty; Phelps, Dale L.; Sanchez, Pablo J.; Carlo, Waldemar A.; Stevenson, David K.; Higgins, Rosemary D.

In: Pediatric Infectious Disease Journal, Vol. 29, No. 7, 01.07.2010, p. 600-606.

Research output: Contribution to journalArticle

D'Angio, CT, Heyne, RJ, O'Shea, TM, Schelonka, RL, Shankaran, S, Duara, S, Goldberg, RN, Stoll, BJ, Van Meurs, KP, Vohr, BR, Das, A, Li, L, Burton, RL, Hastings, B, Phelps, DL, Sanchez, PJ, Carlo, WA, Stevenson, DK & Higgins, RD 2010, 'Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants', Pediatric Infectious Disease Journal, vol. 29, no. 7, pp. 600-606. https://doi.org/10.1097/INF.0b013e3181d264a6
D'Angio, Carl T. ; Heyne, Roy J. ; O'Shea, T. Michael ; Schelonka, Robert L. ; Shankaran, Seetha ; Duara, Shahnaz ; Goldberg, Ronald N. ; Stoll, Barbara J. ; Van Meurs, Krisa P. ; Vohr, Betty R. ; Das, Abhik ; Li, Lei ; Burton, Robert L. ; Hastings, Betty ; Phelps, Dale L. ; Sanchez, Pablo J. ; Carlo, Waldemar A. ; Stevenson, David K. ; Higgins, Rosemary D. / Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. In: Pediatric Infectious Disease Journal. 2010 ; Vol. 29, No. 7. pp. 600-606.
@article{b61946c823be49e2acd4b0c108b6563b,
title = "Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants",
abstract = "Background: The heptavalent pneumococcal CRM197 conjugate vaccine (PCV-7) has been incompletely studied in very-low-birth-weight (≤1500 g) infants. Objective: To assess PCV-7 immunogenicity in very-low-birth-weight, premature infants. We hypothesized that the frequency of postvaccine antibody concentrations 0.15 μg/mL would vary directly with birth weight. Methods: This was a multicenter observational study. Infants 401 to 1500 g birth weight and <32 0/7 weeks gestation, stratified by birth weight, were enrolled from 9 National Institute of Child Health and Human Development Neonatal Research Network centers. Infants received PCV-7 at 2, 4, and 6 months after birth and had blood drawn 4 to 6 weeks following the third dose. Antibodies against the 7 vaccine serotypes were measured by enzyme-linked immunosorbent assay. Results: Of 369 enrolled infants, 244 completed their primary vaccine series by 8 months and had serum obtained. Subjects were 27.8 ± 2.2 (mean ± standard deviation) weeks gestation and 1008 ± 282 g birth weight. Twenty-six percent had bronchopulmonary dysplasia and 16{\%} had received postnatal glucocorticoids. Infants 1001 to 1500 g birth weight were more likely than those 401 to 1000 g to achieve antibody concentrations 0.15 μg/mL against the least 2 immunogenic serotypes (6B: 96{\%} vs. 85{\%}, P = 0.003 and 23F: 97{\%} vs. 88{\%}, P = 0.009). In multiple logistic regression analysis, lower birth weight, postnatal glucocorticoid use, lower weight at blood draw, and Caucasian race were each independently associated with antibody concentrations <0.35 μg/mL against serotypes 6B and/or 23F. Conclusions: When compared with larger premature infants, infants weighing ≤1000 g at birth have similar antibody responses to most, but not all, PCV-7 vaccine serotypes.",
keywords = "immunization, pneumococcal vaccines, premature infant, vaccines, very low birth weight infant",
author = "D'Angio, {Carl T.} and Heyne, {Roy J.} and O'Shea, {T. Michael} and Schelonka, {Robert L.} and Seetha Shankaran and Shahnaz Duara and Goldberg, {Ronald N.} and Stoll, {Barbara J.} and {Van Meurs}, {Krisa P.} and Vohr, {Betty R.} and Abhik Das and Lei Li and Burton, {Robert L.} and Betty Hastings and Phelps, {Dale L.} and Sanchez, {Pablo J.} and Carlo, {Waldemar A.} and Stevenson, {David K.} and Higgins, {Rosemary D.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1097/INF.0b013e3181d264a6",
language = "English",
volume = "29",
pages = "600--606",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants

AU - D'Angio, Carl T.

AU - Heyne, Roy J.

AU - O'Shea, T. Michael

AU - Schelonka, Robert L.

AU - Shankaran, Seetha

AU - Duara, Shahnaz

AU - Goldberg, Ronald N.

AU - Stoll, Barbara J.

AU - Van Meurs, Krisa P.

AU - Vohr, Betty R.

AU - Das, Abhik

AU - Li, Lei

AU - Burton, Robert L.

AU - Hastings, Betty

AU - Phelps, Dale L.

AU - Sanchez, Pablo J.

AU - Carlo, Waldemar A.

AU - Stevenson, David K.

AU - Higgins, Rosemary D.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background: The heptavalent pneumococcal CRM197 conjugate vaccine (PCV-7) has been incompletely studied in very-low-birth-weight (≤1500 g) infants. Objective: To assess PCV-7 immunogenicity in very-low-birth-weight, premature infants. We hypothesized that the frequency of postvaccine antibody concentrations 0.15 μg/mL would vary directly with birth weight. Methods: This was a multicenter observational study. Infants 401 to 1500 g birth weight and <32 0/7 weeks gestation, stratified by birth weight, were enrolled from 9 National Institute of Child Health and Human Development Neonatal Research Network centers. Infants received PCV-7 at 2, 4, and 6 months after birth and had blood drawn 4 to 6 weeks following the third dose. Antibodies against the 7 vaccine serotypes were measured by enzyme-linked immunosorbent assay. Results: Of 369 enrolled infants, 244 completed their primary vaccine series by 8 months and had serum obtained. Subjects were 27.8 ± 2.2 (mean ± standard deviation) weeks gestation and 1008 ± 282 g birth weight. Twenty-six percent had bronchopulmonary dysplasia and 16% had received postnatal glucocorticoids. Infants 1001 to 1500 g birth weight were more likely than those 401 to 1000 g to achieve antibody concentrations 0.15 μg/mL against the least 2 immunogenic serotypes (6B: 96% vs. 85%, P = 0.003 and 23F: 97% vs. 88%, P = 0.009). In multiple logistic regression analysis, lower birth weight, postnatal glucocorticoid use, lower weight at blood draw, and Caucasian race were each independently associated with antibody concentrations <0.35 μg/mL against serotypes 6B and/or 23F. Conclusions: When compared with larger premature infants, infants weighing ≤1000 g at birth have similar antibody responses to most, but not all, PCV-7 vaccine serotypes.

AB - Background: The heptavalent pneumococcal CRM197 conjugate vaccine (PCV-7) has been incompletely studied in very-low-birth-weight (≤1500 g) infants. Objective: To assess PCV-7 immunogenicity in very-low-birth-weight, premature infants. We hypothesized that the frequency of postvaccine antibody concentrations 0.15 μg/mL would vary directly with birth weight. Methods: This was a multicenter observational study. Infants 401 to 1500 g birth weight and <32 0/7 weeks gestation, stratified by birth weight, were enrolled from 9 National Institute of Child Health and Human Development Neonatal Research Network centers. Infants received PCV-7 at 2, 4, and 6 months after birth and had blood drawn 4 to 6 weeks following the third dose. Antibodies against the 7 vaccine serotypes were measured by enzyme-linked immunosorbent assay. Results: Of 369 enrolled infants, 244 completed their primary vaccine series by 8 months and had serum obtained. Subjects were 27.8 ± 2.2 (mean ± standard deviation) weeks gestation and 1008 ± 282 g birth weight. Twenty-six percent had bronchopulmonary dysplasia and 16% had received postnatal glucocorticoids. Infants 1001 to 1500 g birth weight were more likely than those 401 to 1000 g to achieve antibody concentrations 0.15 μg/mL against the least 2 immunogenic serotypes (6B: 96% vs. 85%, P = 0.003 and 23F: 97% vs. 88%, P = 0.009). In multiple logistic regression analysis, lower birth weight, postnatal glucocorticoid use, lower weight at blood draw, and Caucasian race were each independently associated with antibody concentrations <0.35 μg/mL against serotypes 6B and/or 23F. Conclusions: When compared with larger premature infants, infants weighing ≤1000 g at birth have similar antibody responses to most, but not all, PCV-7 vaccine serotypes.

KW - immunization

KW - pneumococcal vaccines

KW - premature infant

KW - vaccines

KW - very low birth weight infant

UR - http://www.scopus.com/inward/record.url?scp=77954349532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954349532&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e3181d264a6

DO - 10.1097/INF.0b013e3181d264a6

M3 - Article

VL - 29

SP - 600

EP - 606

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 7

ER -